Market Place
Sourcing Support
Viz.ai, Alnylam Partner In Cardiac Amyloidosis Care
24 Mar 2026 //
BUSINESSWIRE
Alnylam To Webcast TTR Investor Webinar
10 Mar 2026 //
BUSSINESSWIRE
Alnylam Hits Profitability In Q4 Despite Amvuttra Revenue Miss
12 Feb 2026 //
FIERCE PHARMA
Alnylam to Conference Call Q4 & Full Year 2025 Financial Results
29 Jan 2026 //
BUSINESSWIRE
Alnylam Unveils 2030 Strategy for Growth and Patient Impact
11 Jan 2026 //
BUSINESSWIRE
Alnylam Pharmaceuticals Announces Changes To Board Of Directors
03 Dec 2025 //
PHARMIWEB
Industry Ceos Express Concern Over Fda`s Capabilities: Survey
21 Nov 2025 //
FIERCE BIOTECH
UK`s drug-cost watchdog recommends Alnylam`s heart disease drug
21 Nov 2025 //
REUTERS
Alnylam To Webcast Q3 2025 Financial Results Conference Call
16 Oct 2025 //
BUSINESS WIRE
Alnylam to Webcast at September Investor Conferences
27 Aug 2025 //
BUSINESSWIRE
Alnylam`s Webcast at Canaccord Genuity 45th Growth Conference
05 Aug 2025 //
BUSINESSWIRE
Alnylam Pharma Q2 2025 Financial Results and Recent Progress
31 Jul 2025 //
BUSINESSWIRE
Alnylam to Webcast Q2 2025 Financial Results Call
17 Jul 2025 //
BUSINESSWIRE
Alnylam Promotes Pushkal Garg to R&D Chief Role
18 Jun 2025 //
BUSINESSWIRE
Alnylam to Webcast at BofA Securities 2025 Health Care Conference
05 May 2025 //
BUSINESSWIRE
Alnylam Pharmaceuticals Reports Q1 2025 Financial Results
01 May 2025 //
BUSINESSWIRE
Alnylam to Discuss Q1 2025 Financial Results in Webcast
17 Apr 2025 //
BUSINESSWIRE
Alnylam presents Phase 3 on Vutrisiran in ATTR-CM at ACC 2025
31 Mar 2025 //
BUSINESSWIRE
FDA Approves Amvuttra (Vutrisiran) for ATTR-CM
21 Mar 2025 //
BUSINESSWIRE
Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum
11 Mar 2025 //
BUSINESSWIRE
Alnylam Showcase Pipeline Advances & Platform Innovation At R&D Day
25 Feb 2025 //
BUSINESSWIRE
Market growth will help spark sales of Amvuttra, Alnylam says
13 Feb 2025 //
FIERCE PHARMA
Alnylam Pharma Reports Q4 & Full Year 2024 Financial Results
13 Feb 2025 //
BUSINESSWIRE
Alnylam to Conference Call FOR Q4 & 2024 Financial Results
30 Jan 2025 //
BUSINESSWIRE
Alnylam to Webcast Presentation at 43rd J.P. Morgan Conference
06 Jan 2025 //
BUSINESSWIRE
Alnylam abandons clinical-stage Type 2 diabetes asset
31 Oct 2024 //
FIERCE BIOTECH
Alnylam to Present TTR Data & Hypertension Program at AHA 2024
30 Oct 2024 //
BUSINESSWIRE
Alnylam to Webcast TTR Investor Day
26 Sep 2024 //
BUSINESSWIRE
Alnylam shares slide after heart drug data fails to impress investors
30 Aug 2024 //
REUTERS
Alnylam To Present HELIOS-B Phase 3 Results At ESC Congress 2024
07 Aug 2024 //
BUSINESSWIRE
Alnylam To Webcast Q2 2024 Financial Results Conference Call
18 Jul 2024 //
BUSINESSWIRE
Alnylam touts `big-win scenario` for closely watched heart trial
25 Jun 2024 //
FIERCE PHARMA
Alnylam Issues 2023 Corporate Responsibility Report
07 May 2024 //
BUSINESSWIRE
Alnylam Reports Q1 2024 Results, Highlights Recent Activity
02 May 2024 //
BUSINESSWIRE
Medison, Alnylam Expand RNAi Deal To More Regions
30 Apr 2024 //
PR NEWSWIRE
Medison, Alnylam Expand RNAi Partnership To More Regions
30 Apr 2024 //
PR NEWSWIRE
Experts paint tough path ahead of Alnylam`s key ATTR-CM readout
22 Apr 2024 //
FIERCE PHARMA
Alnylam To Webcast Q1 2024 Financial Results Call
18 Apr 2024 //
BUSINESSWIRE
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign
13 Mar 2024 //
BUSINESSWIRE
Alnylam takes a family road trip to talk about health history
13 Mar 2024 //
ENDPTS
Roche, Alnylam say blood pressure drug succeeds in mid-stage trial
06 Mar 2024 //
BIOPHARMA DIVE
Alnylam Reports Positive KARDIA-2 Topline Study Results
05 Mar 2024 //
BUSINESSWIRE
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
27 Feb 2024 //
BUSINESSWIRE
Alnylam CEO defends changes to crucial ATTR trial
22 Feb 2024 //
ENDPTS
Alnylam Reports Fourth Quarter and Full Year 2023 Financial Results
15 Feb 2024 //
BUSINESSWIRE
Alnylam`s last-minute Amvuttra trial change raises doubts
15 Feb 2024 //
FIERCE PHARMA
Alnylam to Webcast Conference Call Discussing Fourth Quarter Financial Results
29 Jan 2024 //
PRESS RELEASE
"Pro Research: Wall Street eyes Alnylam`s RNAi therapeutics potential "
21 Jan 2024 //
PRESS RELEASE
Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year
09 Jan 2024 //
BUSINESSWIRE
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Revenues
07 Jan 2024 //
BUSINESSWIRE
Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
BUSINESSWIRE
Alnylam Highlights Progress with Platform Innovation and Pipeline at R&D Day
13 Dec 2023 //
BUSINESSWIRE
Alnylam to Webcast Virtual R&D Day
06 Dec 2023 //
PRESS RELEASE
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023
30 Nov 2023 //
PRESS RELEASE
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
07 Nov 2023 //
BUSINESSWIRE
Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration Revenues
03 Nov 2023 //
NASDAQ
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
BUSINESSWIRE
Alnylam Recognized by Magazine as Top Employer for Fifth Consecutive Year
26 Oct 2023 //
BUSINESSWIRE
Alnylam, Biogen build noise in Alzheimer`s with gene silencing
26 Oct 2023 //
FIERCE BIOTECH
Alnylam to Webcast Conference Discussing Third Quarter 2023 Financial Results
19 Oct 2023 //
BUSINESSWIRE
